Multiple sclerosis
Neurology· 5 reviewed drugs· 5350 cited findings behind them
What the regulatory reviews cover
This page provides an overview of drugs reviewed by regulatory bodies for the treatment of multiple sclerosis (MS). The drugs included are Briumvi, Ocrevus/ocrelizumab, Fampyra, Kesimpta, and Vumerity. These drugs address various forms of MS, including relapsing forms, clinically isolated syndrome, relapsing-remitting disease, active secondary progressive disease, and walking disability associated with MS.
Reported outcomes include Briumvi's Annualized Relapse Rate (ARR) of 0.09 compared to a comparator ARR of 0.23. Ocrevus/ocrelizumab demonstrated a Relapse rate reduction vs Rebif of 46. Fampyra showed a Relative risk of improvement in walking ability of 1.38. Kesimpta achieved an Annualized Relapse Rate (ARR) reduction of 58.5%. Vumerity reported an Annualized relapse rate (ARR) with ALKS 8700 of 0.17. It is important to note that these figures are derived from different trials and are not directly comparable head-to-head.
The drugs — one cited result each
| Briumvi TG THERAPEUTICS, INC | Annualized Relapse Rate (ARR): 0.09 TG THERAPEUTICS, INC — Briumvi FDA Review (BLA761238, ORIG 1, p.52 |
| Ocrevus/ocrelizumab Roche Holding AG | Relapse rate reduction vs Rebif: 46 Roche Holding AG — Ocrevus FDA Review (BLA761053, ORIG 1, 20, p.198 |
| Fampyra Merz Pharma | Relative risk of improvement in walking ability: 1.38 Merz — Fampyra EMA EPAR variation assessment report (EMEA/H/, p.6 |
| Kesimpta Novartis AG | Annualized Relapse Rate (ARR) reduction: 58.5% Novartis AG — Kesimpta FDA Review (BLA125326, SUPPL 70, 2020, p.43 |
| Vumerity Biogen Inc. | Annualized relapse rate (ARR) with ALKS 8700: 0.17 Biogen Inc. — Vumerity FDA Review, p.56 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Neurology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.